A real‐world study of alemtuzumab in a cohort of Italian patients
Cinzia Valeria Russo(University of Naples Federico II), Alessio Signori(University of Genoa), Alessia Giugno(University of Bari Aldo Moro), Damiano Baroncini, Arianna Sartori(Azienda Sanitaria Universitaria Integrata di Trieste), Jessica Frau(University of Cagliari), Alice Laroni(Azienda Ospedaliera di Padova), Laura Brambilla(Anna Needs Neuroblastoma Answers), Elisabetta Signoriello(ATS Sardegna (Italy)), Valentina Torri Clerici, Francesco Saccà(Federico II University Hospital), Stefania Federica De Mercanti(University of Turin), Antonio Carotenuto, Sara La Gioia(Ospedale Papa Giovanni XXIII), Simona Bonavita, Maria Pia Sormani(University of Genoa), Paola Cavalla, Marinella Clerico(Ospedale San Luigi Gonzaga), Caterina Lapucci(Université de Bordeaux), Valeria Di Francescantonio, Marco Capobianco(Ospedale San Luigi Gonzaga), Giuseppe Fenu(University of Cagliari), Roberta Grasso(Ospedale Papa Giovanni XXIII), Rosa Iodice, Cinzia Cordioli(Ospedale Policlinico San Martino), Giacomo Lus(University of Campania "Luigi Vanvitelli"), Antonio Gallo(University of Campania "Luigi Vanvitelli"), Eleonora Cocco(University of Cagliari), Francesca Caleri(Krankenhaus Meran), Pietro Annovazzi(Vita-Salute San Raffaele University), Giorgia Teresa Maniscalco(Ospedale Antonio Cardarelli), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla)
Cited by 26
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Multiple Sclerosis Severity Score
|Neurology|2005|959
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
|Journal of Neuroinflammation|2016|896
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624